<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932513</url>
  </required_header>
  <id_info>
    <org_study_id>SBP-9200-HBV-203</org_study_id>
    <nct_id>NCT03932513</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients</brief_title>
  <official_title>A Phase 2, Open-label Study Evaluating the Intra-hepatic Effect of Inarigivir 400 mg Per Day and 400 mg Three Times Per Week on Immune Response and Viral Markers in Virally Suppressed Patients With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spring Bank Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSI Medical Research Pte Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spring Bank Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose
      per day and three times per week on immune response and viral markers in virally suppressed
      patients with chronic hepatitis B infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, open-label, study to evaluate the intra-hepatic effect of inarigivir
      dose per day and three times per week on immune response and viral markers in virally
      suppressed patients with chronic hepatitis B infection
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was halted due to suspected liver injury in another study with Inarigavir
  </why_stopped>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Actual">December 21, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intra-hepatic immune response</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Relative change from Baseline to Week 6 of intra-hepatic immune response (quantitative measurement of 500-600 genes using Nanostring technology) in hepatocytes and liver immune cells derived from the central immunology core biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intra-hepatic anti-viral response</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Relative change from Baseline to Week 6 of intra-hepatic anti-viral response (HBV DNA, HBV RNA, HBV core levels, cccDNA and HBsAg levels) using PCR assays in hepatocytes and liver immune cells derived from the intra-hepatic virology biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with an adverse event (AE), or a clinically significant clinical laboratory abnormality</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of patients during the Baseline to Week 6 inarigivir treatment period with an adverse event (AE), or a clinically significant clinical laboratory abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change of intra-hepatic immune markers, serum cytokines and PBMC activation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Correlation of change from Baseline to Week 6 of intra-hepatic immune markers, serum cytokines and PBMC activation measured by interferon-stimulated gene (ISG) production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of change of intra-hepatic antiviral response and serum anti-viral response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Correlation of change from Baseline to Week 6 of intra-hepatic antiviral response and serum anti-viral response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of change of intra-hepatic biomarkers of immune activation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of intra-hepatic biomarkers of immune activation between inarigivir 400 mg per day and 400 mg three times per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of change of peripheral biomarkers of immune activation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of intra-hepatic and peripheral biomarkers of immune activation and anti-viral response between inarigivir 400 mg per day and 400 mg three times per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of change of anti-viral response</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of change in mRNA expression using Nanostring Technology, from Baseline to Week 6 of anti-viral response between inarigivir 400 mg per day and 400 mg three times per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of hepatic immune cells</measure>
    <time_frame>6 weeks</time_frame>
    <description>Characterization by immuno-phenotyping of hepatic immune cells at Baseline and Week 6. Hepatic immune cells are analyzed and sorted by phenotype using markers of cell activation status through flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of exhaustion markers</measure>
    <time_frame>6 weeks</time_frame>
    <description>Characterization by immuno-phenotyping of exhaustion markers at Baseline and Week 6. Hepatic immune cells are analyzed and sorted by phenotype using markers T cell exhaustion through flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>HBV</condition>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Treatment A: inarigivir soproxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir 400 mg once per day for 6 weeks (2800mg/week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: inarigivir soproxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inarigivir 400 mg three times per week for 6 weeks (1200mg/week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inarigivir soproxil</intervention_name>
    <description>Inarigivir 200mg and 400mg oral tablets, once daily</description>
    <arm_group_label>Treatment A: inarigivir soproxil</arm_group_label>
    <arm_group_label>Treatment B: inarigivir soproxil</arm_group_label>
    <other_name>SB 9200</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged ≥ 21 to ≤ 70 years

          2. Chronic hepatitis B infection defined as HBsAg positive and on NUC therapy for at
             least one year.

               1. Have at least one prior documented result of HBV DNA ≤ 20 IU/mL LLOQ from a local
                  laboratory, 6 or more months prior to Screening

               2. HBV DNA ≤ 20 IU/mL at Screening tested by the Central Laboratory

               3. Have been on a commercially available HBV oral antiviral (OAV) treatment(s)
                  (tenofovir alafenamide, tenofovir disoproxil fumarate, entecavir, adefovir,
                  lamivudine, telbivudine, either as single agents or in combination) with no
                  change in regimen for 3 months prior to screening.

          3. Ultrasound, computed tomography (CT) scan, or magnetic resonance imaging (MRI) within
             3 months of randomization date with no evidence of hepatocellular carcinoma

          4. Must be willing and able to comply with all study requirements including two liver
             biopsies

          5. Negative urine or serum pregnancy test (for women of childbearing potential documented
             within the 24-hour period prior to the first dose of test drug. If the urine pregnancy
             test is positive, a follow-up serum test is required for confirmation. Additionally,
             all fertile males with partners of childbearing age and females must be using reliable
             contraception during the study and for 3 months after treatment completion. All
             fertile males must also refrain from sperm donation while on Active drug and for 3
             months after completion of Active drug.

          6. Must have the ability to understand and sign a written informed consent form; consent
             must be obtained prior to initiation of study procedures

        Exclusion Criteria:

          1. Any liver biopsy evidence of metavir F3 or F4 disease on any prior biopsy

          2. Any history of decompensation of liver disease including history of ascites,
             encephalopathy, or varices

          3. Evidence of advanced fibrosis at screening as defined by Fibroscan at the Screening
             Visit of ≥ 8 kilopascals

          4. Laboratory parameters not within defined thresholds: ALT or AST ≥ 40 IU, white blood
             cells &lt; 4500 cells/μL (SI unit &lt; 4.5 × 109/L), hemoglobin (HgB) &lt; 12 g/dL (SI unit &lt;
             120 g/L) for females, &lt; 13 g/dL (SI unit &lt; 130 g/L) for males, platelets &lt; 150,000 per
             μL (SI unit &lt; 150 × 109/L), albumin &lt; 3.5 g/dL (SI unit &lt; 35 g/L), international
             normalized ratio (INR) &gt; 1.5, total bilirubin &gt; 1.2 mg/dL (SI unit &gt; 20.52 μmol/L), or
             alpha-fetoprotein (AFP) &gt; 50 ng/mL (SI unit &gt; 180.25 nmol/L). Patients with an
             elevated indirect bilirubin and known Gilbert's disease can be included if direct
             bilirubin is within normal limits. Patients with an AFP &gt; 50 ng/mL but ˂ 500 ng/mL can
             be included if computed tomography (CT) scan or magnetic resonance imaging (MRI)
             performed within 3 months shows no evidence of hepatocellular carcinoma.

          5. Creatinine &gt; 1.2 mg/dL (SI unit &gt; 106.08 μmol/L), creatinine clearance &lt; 50 mL/min (SI
             unit &lt; 0.83 L/s/m2)

          6. Co-infection with hepatitis C virus, human immunodeficiency virus, or hepatitis D
             virus

          7. Evidence or history of hepatocellular carcinoma

          8. Malignancy within 5 years prior to Screening, with the exception of specific cancers
             that are cured by surgical resection (basal cell skin cancer, etc.). Patients under
             evaluation for possible malignancy are not eligible.

          9. Significant cardiovascular, pulmonary, or neurological disease

         10. Received solid organ or bone marrow transplant

         11. Received within 3 months of Screening or expected to receive prolonged therapy with
             immunomodulators (e.g., corticosteroids) or biologics (e.g., monoclonal antibody,
             Interferon)

         12. Patients currently taking medication(s) that are transported through organic anion
             transporting polypeptide 1 including, but not limited to, atazanavir, rifampin,
             cyclosporine, eltrombopag, gemfibrozil, lopinavir/ritonavir, and saquinavir

         13. Use of any herbal medications or supplements during the study period

         14. Use of another investigational agent within 3 months of Screening

         15. Current alcohol or substance abuse judged by the Investigator to potentially interfere
             with compliance

         16. Females who are pregnant or may wish to become pregnant during the study

         17. If the Investigator believes the prospective patient will not be able to comply with
             the requirements of the protocol and complete the study

         18. Any medical condition, in the opinion of the Investigator, that could interfere with
             evaluation of the study objectives or safety of the patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Lim Seng Gee</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

